152 related articles for article (PubMed ID: 30940668)
1. Tc-99m HYNIC-TOC scintigraphy in dedifferentiated thyroid cancer.
Agrawal K; Patro PSS; Preetam C
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30940668
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers.
Sager S; Kabasakal L; Halac M; Maecke H; Uslu L; Önsel Ç; Kanmaz B
Clin Nucl Med; 2013 May; 38(5):321-5. PubMed ID: 23531772
[TBL] [Abstract][Full Text] [Related]
4. [The role of scintigraphy with the use of 99mTc-HYNIC-TOC in the diagnosis of medullary thyroid carcinoma].
Czepczyński R; Kosowicz J; Ziemnicka K; Mikołajczak R; Gryczyńska M; Sowiński J
Endokrynol Pol; 2006; 57(4):431-5. PubMed ID: 17006849
[TBL] [Abstract][Full Text] [Related]
5. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
[TBL] [Abstract][Full Text] [Related]
7. (99m)Tc HYNIC-TOC imaging and 177Lu DOTA-octreotate treatment in non-iodine-concentrating dedifferentiated thyroid carcinoma metastases: an unusual alternative diagnosis.
Basu S; Joshi A
Clin Nucl Med; 2014 Jul; 39(7):632-4. PubMed ID: 24873792
[TBL] [Abstract][Full Text] [Related]
8. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
[TBL] [Abstract][Full Text] [Related]
9. 99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans.
Gabriel M; Froehlich F; Decristoforo C; Ensinger C; Donnemiller E; von Guggenberg E; Heute D; Moncayo R
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):330-41. PubMed ID: 14625664
[TBL] [Abstract][Full Text] [Related]
10. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment.
Czepczyński R; Gryczyńska M; Ruchała M
Nucl Med Rev Cent East Eur; 2016; 19(2):67-73. PubMed ID: 27479883
[TBL] [Abstract][Full Text] [Related]
11. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: a comparison of lesions with 18F-FDG-PET and MIBI images.
Sager S; Kabasakal L; Ocak M; Maecke H; Uslu L; Halaç M; Asa S; Sager G; Önsel Ç; Kanmaz B
Nucl Med Commun; 2013 Dec; 34(12):1190-5. PubMed ID: 24121313
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of
Chen H; Li Y; Gao X; Shen X
Clin Imaging; 2018; 52():365-369. PubMed ID: 30248495
[TBL] [Abstract][Full Text] [Related]
14. Clinical Value of
Gao R; Zhang GJ; Wang YB; Liu Y; Wang F; Jia X; Liang YQ; Yang AM
Sci Rep; 2018 Jan; 8(1):473. PubMed ID: 29323252
[TBL] [Abstract][Full Text] [Related]
15. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.
Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247
[TBL] [Abstract][Full Text] [Related]
17. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
18. Cerebellar metastasis of papillary thyroid carcinoma detected with somatostatin receptor scintigraphy.
Czepczyński R; Wyszomirska A; Gryczyńska M; Szczepanek-Parulska E; Ruchała M
Endokrynol Pol; 2018; 69(1):24-27. PubMed ID: 29319129
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
Trogrlic M; Tezak S
Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
[TBL] [Abstract][Full Text] [Related]
20. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
